Table 2.
Author | Year | KOOS | KOOS-S | KOOS-P | KOOS-ADLs | KOOS-Sp | KOOS-QOL | WOMAC | EQOL | VAS | IKDC | TLK | KSS | LEAS | OKS | EQ-5D | IKS | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | B | FU | ||
Russo et al. (10)** | 2017 | / | 20 | / | 21 | / | 19 | / | 17 | / | 15 | / | 13 | 2,4 | 20 | 31 | |||||||||||||||||
Russo et al. (3) **** | 2018 | / | 64 | / | 55 | / | 55 | / | 41 | ||||||||||||||||||||||||
Panchal et al. (5) | 2018 | 5,7 | 4,3 | 74 | 82 | 37 | 42 | ||||||||||||||||||||||||||
Cattaneo et al. (11)*** | 2018 | / | 23 | / | 24 | / | 27 | / | 38 | / | 40 | / | 26 | ||||||||||||||||||||
Mautner et al. (1) | 2019 | 55 | 68 | 51 | 70 | 57 | 76 | 21 | 46 | 29 | 48 | 0,67 | 0,77 | 4,3 | 2,8 | ||||||||||||||||||
Hudetz et al. (7) | 2019 | 48 | 70 | 39 | 65 | 40 | 64 | 16 | 35 | 13 | 37 | 55 | 32 | 4 | 0,7 | ||||||||||||||||||
Schiavone Panni et al. (12) | 2019 | 8,5 | 5,1 | 47 | 73 | ||||||||||||||||||||||||||||
Bisicchia et al. (15) | 2019 | 55 | 18 | 6,2 | 2,6 | 26 | 45 | 17 | 73 | ||||||||||||||||||||||||
Heidari et al. (9)* | 2020 | 7 | 3 | 25 | 34 | 0,62 | 0,69 |
* Median values; ** Average median improvement related to baseline; *** Average mean improvement related to baseline; **** Improvement in percentage related to baseline.
Abbreviations: KOOS, Knee Osteoarthritis and Injury Outcome Score, S, Symptoms subscale, P, Pain subscale, ADLs, Activities of Daily Living subscale, Sp, Sports subscale, QOL, Quality Of Life subscale; WOMAC, Western Ontario and Mc Master University; EQOL, Emory Quality of Life ; VAS, Visual Analog Scale; IKDC, International knee documentation committee; TLK, Tegner Lysholm Knee; KSS, Knee Society Score; LEAS, Lower Extremity Activity Scale; OKS, Oxford Knee Score; EQ-5D, EuroQol 5D; IKS, International Knee Society score; B, Basline; FU, FollowUp.